Diabetes is occurring in epidemic proportions around the globe. Using the WHO global database, King and colleagues have estimated that the number of adults with diabetes will increase from 135 million in 1995 to 300 million in 2025, with a predicted world diabetes prevalence of 5.4% [1] . Most of these future cases are expected to occur in the developing world, but the prevalence of self-reported diabetes in the United States has already increased, from 4.9% in 1990 to 7.3% in 2000 [2] . Women are more likely to develop diabetes [2] , and since women with diabetes have not experienced the same reduction in cardiovascular outcomes as men with diabetes in recent years [3] , it can be a particularly devastating disease for them.
Treating diabetes has improved health outcomes and quality of life, but prevention of the disease will have a much greater impact on public health. The Diabetes Prevention Program (DPP) found that intensive lifestyle interventions, with the aim of modest weight reduction and 150 minutes of exercise a week, considerably reduced the number of high-risk subjects who developed diabetes over a three-year period [4] , but translation of these findings into the clinical setting has been difficult. Health care systems have been slow to invest in the labour-intensive systems necessary to support patients as they change their lifestyles. Also, very few patients have succeeded in maintaining weight loss over the longer term without the type of support available in the DPP. Medications such as metformin, troglitazone and acarbose have also been studied in terms of diabetes prevention [4, 5, 6] . Although effective, they have had significantly less impact than intensive lifestyle changes alone and may simply postpone the inevitable presentation of diabetes in individuals at risk. Additional strategies to prevent diabetes are clearly needed.
This issue of the journal features a report from the Women's Health Initiative (WHI) that offers new insights into how diabetes may be prevented in women [7] . The study was designed to examine the effect of post-menopausal hormone replacement on a number of health outcomes, with a primary endpoint of coronary heart disease death or non-fatal myocardial infarction. More than 15,000 women were randomised to receive either 0.625 mg of conjugated equine oestrogens and 2.5 mg of medroxyprogesterone acetate or placebo each day. The study was halted after an average of 5.6 years of follow-up because of adverse events in the intervention arm. Evaluation of the data after the end of the study did, however, reveal that women randomised to hormone therapy had a lower incidence of self-reported diabetes than those randomised to placebo. The cumulative incidence of treated diabetes was 3.5% in the hormone treated group vs 4.2% in the control group, with a hazard ratio of 0.79 (nominal 95% CI 0.67-0.93). Interestingly, the hazard ratio was unaffected by adjustment for changes in body mass index or waist circumference.
Whilst confirming the secondary endpoint observations made by the Heart and Estrogen/Progestin Replacement Study (HERS) in post-menopausal women with coronary disease [8] , Margolis and colleagues were able to progress towards an understanding of the mechanisms involved, in that a subset of their participants also had blood obtained for fasting glucose and insulin at baseline and during follow-up. This randomly selected cohort represented 8.6% of the population and was stratified by age, clinical centre and ethnicity to oversample minority women. At one year of follow-up, HOMA-IR, a measure of insulin sensitivity calculated from fasting levels of glucose and insulin [9] , was significantly lower in women on hormone replacement. By Year 3, this difference in HOMA-IR had disappeared, probably because of lower numbers and poorer adherence to the hormone regimen, but the observations provide evidence that reduced insulin resistance may be the mechanism by which hormone replacement therapy reduced the incidence of diabetes in this group.
Why should hormone replacement therapy reduce insulin resistance? It is unlikely that progestin alone is responsible, since such agents have been shown to be associated with an increase in the incidence of diabetes in women using the drug for contraception [10] . Oestrogen alone might be responsible, but conclusions cannot be reached until all of the data from the WHI Estrogen alone study can be analysed [11] . Oestrogen is, however, known to increase serum sex hormone binding globulin (SHBG), thereby reducing free testosterone concentrations and increasing insulin sensitivity in post-menopausal women [12] . Does this imply that women at risk of getting diabetes should be treated with oestrogen? Probably not, given the increased risk of stroke and pulmonary embolism seen in women treated with oestrogen alone in the WHI [11] . But these observations do suggest that a better understanding of how oestrogen alters insulin sensitivity could lead to new therapies for use in the prevention of diabetes. Although the selective oestrogen receptor modulator, raloxifene, does not appear to modify insulin sensitivity in the same way as oestrogen [13] , further investigation of drugs with oestrogenic qualities could lead to an agent that improves insulin sensitivity without increasing the risk of cancer or cardiovascular events.
Meanwhile, the WHI has shown that post-menopausal women randomised to hormone replacement therapy are less likely to progress to diabetes, possibly because of reduced insulin resistance. The effect on insulin resistance appeared unrelated to changes in body mass index, but randomised trials like the Diabetes Prevention Project [4] or Finnish Diabetes Prevention Study [14] suggest that lowering insulin resistance through weight reduction and/or increased exercise also reduces the incidence of diabetes. So while the search for useful therapies continues, women and men at risk of diabetes would be well advised to continue to eat less and exercise more. 
